Nel Moore, PHD

Chair of the Scientific Advisory Board

During a 21-year career in the pharmaceutical industry Nel has gained wide experience in global drug discovery and development in the areas of Immunology, Oncology and Anti-Infectives. As Global Product Vice President in AstraZeneca, she led the development, submission and approval of Zavicefta^TM. She went on to design, build and lead the Antibiotics Development organization as part of a semi-autonomous Antibiotics Business Unit within AstraZeneca. Until divestment of the portfolio to Pfizer, this development organization supported four antibiotics in various stage of development and commercialization.

During her time in Oncology, Nel led the Global Product Teams responsible for the first launch of IRESSA^TM as 1st line for EGFR mutation positive patients in Europe, and the 500mg world-wide label extensions for
Faslodex^TM.

Nel started her pharmaceutical career leading the Research Department for Respiratory and Inflammation Biology responsible for taking molecules into preclinical development, and early clinical studies.

Nel has a BSc Hons and a PhD in Medical Biochemistry from Birmingham University (UK), and is currently Chair of the Board for CHAIN Biotechnology, and a non-executive director for PhagoMed. At CARB-X, Nel chairs the pre- and post-award scientific advisory boards.